Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.


  • Study type

  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Rochester, Minnesota: 13-004966
    NCT ID: NCT01956929
    Sponsor Protocol Number: 13-004966

About this study

This study is being done to understand metformin's mechanisms of action regarding glucose production, protein metabolism, and mitochondrial function.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • 35-65 years of age
  • Fasting blood glucose >100 mg/dl
  • BMI 27-36 kg/m2
  • Waist Circumference: Men ≥ 104 cm; women ≥ 88 cm
  • If previously on anti-diabetic medication, should be off for at least 1 month

Exclusion Criteria:

  • Active use of hypoglycemic agents (< 1 month)
  • Renal failure, creatinine ≥ 1.5 mg/dL in men or ≥ 1.4 mg/dL in women
  • Alanine aminotransferase levels exceed 135 IU/L or aspartate aminotransferase levels exceed 129 IU/L (3 x the upper limit of normal)
  • Congestive Heart Failure (EF < 40 %)
  • Active coronary artery disease
  • Recent (less than 6 weeks) or planned imaging study requiring IV contrast
  • Participation in structured exercise (> 2 hr per week)
  • Recent change in dietary habits or weight
  • Tobacco use
  • Use of systemic glucocorticoids
  • Anti-coagulant therapy (warfarin/heparin)
  • Pregnancy or breastfeeding
  • Alcohol consumption greater than 2 drinks/day
  • Uncontrolled Hypothyroidism, abnormal thyroid stimulating hormone levels
  • Metformin Allergy

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

K Sreekumaran Nair, M.D., Ph.D.

Closed for enrollment

Contact information:

Raul Ruiz M.D.



Mayo Clinic Footer